Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb Multicentre, Double-Blind, Dose-Ranging, Randomised, Placebo-Controlled Study Evaluating Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism

NCT02730169 is registered in ClinicalTrials.gov with Mereo BioPharma as lead sponsor.

NCT NCT02730169
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02730169 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb Multicentre, Double-Blind, Dose-Ranging, Randomised, Placebo-Controlled Study Evaluating Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism
Lead sponsor
Mereo BioPharma
Phase
Phase 2
Overall status
Completed
Start date
May 12, 2016
Completion date
May 19, 2018
Enrollment
271 (actual)
Sites
63

Conditions

As the registry lists them; a condition with its own page is linked.

hypogonadotropic hypogonadism